ALFA Finder
17:23 IST
NSE
Earnings Call
Alkem Laboratories Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹4,520 Cr (+13.8%) and EBITDA margin 22.5%, but PAT fell 11.7%. US constant-currency sales contracted 3% on price erosion.
Alkem Laboratories Ltd
Alkem Laboratories Ltd news stories on ALFA NewsRead the news →- Share price
- ₹5,114.00
- Market cap
- ₹61,146 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.6×Sector 43.7×
- Promoter holding
- 49.70%+0.00% QoQ
- FII holding
- 10.32%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Management Change 10Merger & Restructuring 7Financial Results 7Legal & Regulatory 5Business Update 5Product Launch 4Other Announcement 4Results Update 3Earnings Call 3Board Meeting Date 3Annual General Meeting 3Results Correction 1Dividend 1Debt & Borrowing 1Capital Structure Change 1Capacity Expansion 1Board Meeting Outcome 1
Time
3 announcements with these filters
18:00 IST
BSE
Earnings Call
Alkem Laboratories Investor Presentation: Key Takeaways
Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.
- Call
- Guides 12% growth
16:27 IST
BSE
Earnings Call
Alkem Laboratories Earnings Call: Key Takeaways
Alkem reported strong FY26 results with landmark INR 3,000cr+ EBITDA. Strategy focuses on chronic therapy growth in India and international expansion, particularly with the semaglutide launch.